Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0002962 (angina)
 21,142 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Action taken by the Food and Drug Administration (FDA) toward the th erapeutic use of estrogens is reported. The FDA has 1st ordered revision of physician-labeling for estrogens, and 2nd has prepared a brochure explaining the advantages and disadvantages of estrogen therapy to patients. Some of the points made in the new labeling and brochure are: 1) the risk of cancer of the uterus increases with duration of use and dosage; 2) users of estrogens should be examined by their physicians at least every 6 months; 3) estrogens should never be given to pregnant women; 4) estrogens should not be given in cases of breast or uterine cancer, undiagnosed abnormal vaginal bleeding, clotting in the legs and lungs, or previous heart disease, angina, or stroke; and 5) estrogens should not be used to treat menopausal nervousness, as they have proved ineffective, or for improving the complexion. There is also no evidence that estrogens are effective in preventing threatened or habitual abortion. It is recommended that estrogens be administered cyclically (3 of 4 weeks), and that the dosage be reduced or discontinued every 3-6 months to assess the need for their continued use.
 ...
PMID:Informing patients about estrogens. 82 30